PMID: 376773May 1, 1979Paper

Transfer of specific unresponsiveness to organ allografts by thymocytes. Specific unresponsiveness by thymocyte transfer

The Journal of Experimental Medicine
W S HendryC B Carpenter

Abstract

Prolonged survival of vascularized organ allografts has been produced in unmodified inbred rats by transfer of thymocytes from enhanced, engrafted, syngeneic animals. For these thymocytes to increase significantly the survival of test allografts they must be harvested 6-9 d after transplantation. Thymectomy of the enhanced, engrafted animals during the same critical period causes acute rejection of othewise long surviving grafts. For optimal effect, the enhanced thymocyte donor must be actively and passively immunized and receive a cardiac allograft. The necessity for erythrocytes in the initial active immunization regimen is noted. Additionally, the antigenic specificity of the suppressor effect has been established with two histoincompatible donor rat strains. Cellular and humoral host responses mounted by test graft recipients after thymocyte transfer from enhanced, engrafted donors are different from those mounted either by unmodifed animals acutely rejecting their grafts or by enhanced rats bearing well-functioning grafts. Numbers of T lymphocytes are reduced in the grafted hearts and in the spleens of test graft recipients, a finding paralleled by the complete absence of specific direct lymphocyte-mediated cytotoxicity. I...Continue Reading

References

Feb 1, 1976·The Journal of Experimental Medicine·J P SoulillouT B Strom
May 1, 1977·The Journal of Experimental Medicine·S Dorsch, R Roser
Jun 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·W Droege
Nov 22, 1969·Lancet·M E French, J R Batchelor
Jun 28, 1968·Science·F P StuartF W Fitch

❮ Previous
Next ❯

Citations

Oct 19, 2007·Journal of the American Society of Nephrology : JASN·Terry B Strom
Sep 1, 1981·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C B Carpenter
Sep 1, 1983·Kidney International·E G Neilson, B Zakheim
Sep 1, 1989·Blood Reviews·G J Schiller, S A Berkman
Jan 1, 1984·Immunological Reviews·N L TilneyT B Strom
Jan 1, 1980·Immunological Reviews·F P StuartF W Fitch
Jun 17, 2004·The Journal of Clinical Investigation·Terry B Strom
Feb 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alberto Sánchez-FueyoXin Xiao Zheng
Mar 1, 1982·Infection and Immunity·S R Wellhausen, D L Boros

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.